{"id":"bh009-docetaxel-injection","safety":{"commonSideEffects":[{"rate":"75–90","effect":"Neutropenia"},{"rate":"50–70","effect":"Anemia"},{"rate":"25–50","effect":"Thrombocytopenia"},{"rate":"20–40","effect":"Peripheral neuropathy"},{"rate":"50–75","effect":"Alopecia"},{"rate":"30–50","effect":"Nausea/vomiting"},{"rate":"40–60","effect":"Fatigue"},{"rate":"20–40","effect":"Fluid retention"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane chemotherapy agent that binds to the β-tubulin subunit of microtubules and prevents their disassembly, leading to cell cycle arrest in the G2/M phase and apoptosis. This mechanism is effective against rapidly dividing cancer cells across multiple tumor types. BH009 is a biosimilar or generic formulation of docetaxel injection.","oneSentence":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:13.800Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Prostate cancer"},{"name":"Gastric cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT04889599","phase":"PHASE3","title":"A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours","status":"COMPLETED","sponsor":"Zhuhai Beihai Biotech Co., Ltd","startDate":"2021-04-29","conditions":"Docetaxel, Solid Tumours, Bioequivalence","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BH009"],"phase":"phase_3","status":"active","brandName":"BH009 (Docetaxel injection)","genericName":"BH009 (Docetaxel injection)","companyName":"Zhuhai Beihai Biotech Co., Ltd","companyId":"zhuhai-beihai-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BH009 (Docetaxel injection) is a treatment for solid tumors, as studied in a bioequivalence trial (NCT04889599) conducted by Zhuhai Beihai Biotech Co., Ltd. The mechanism of action of BH009 is unknown, as per ChEMBL database information.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}